Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 12/20 | 0.65 |
| ▸ | LCK | P06239 | 11/20 | 0.65 |
| ▸ | TEK | Q02763 | 11/20 | 0.65 |
| ▸ | KDR | P35968 | 6/20 | 0.65 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.59 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.59 |
| ▸ | BTK | Q06187 | 6/20 | 0.59 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.55 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 7/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.55 |
| ▸ | IGF1R | P08069 | 3/20 | 0.55 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.55 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.55 |
| ▸ | PLK4 | O00444 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.53 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL6466940 | 1.00 | SRC (0.65) | SRCLCKTEKKDRNUDT14 | |
| Acetic Acid SCHEMBL6465241 | 0.91 | SRC (0.64) | SRCLCKTEKKDRNUDT14 | |
| Acetic Acid SCHEMBL6465247 | 0.91 | SRC (0.64) | SRCLCKTEKKDRNUDT14 | |
| SCHEMBL6434044 | 0.89 | LCK (0.79) | SRCLCKTEKKDRNUDT14 | |
| SCHEMBL6432743 | 0.89 | LCK (0.79) | SRCLCKTEKKDRNUDT14 | |
| SCHEMBL6432739 | 0.89 | LCK (0.79) | SRCLCKTEKKDRNUDT14 | |
| Acetic Acid SCHEMBL6431451 | 0.88 | SRC (0.66) | SRCLCKTEKKDRNUDT14 | |
| Acetic Acid SCHEMBL6462699 | 0.88 | SRC (0.68) | SRCLCKTEKKDRNUDT14 | |
| Acetic Acid SCHEMBL6462695 | 0.88 | SRC (0.68) | SRCLCKTEKKDRNUDT14 | |
| SCHEMBL6463745 | 0.86 | LCK (0.69) | SRCLCKTEKKDRNUDT14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| WO-2004100868-A2 | METHOD OF TREATING TRANSPLANT REJECTION | ABBOTT LABORATORIES (US) | 2004-11-25 | — | — | WO | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | SRC 46/4885LCK 1/4885TEK 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.